s1904 cd19 car-t
Cell therapyexperimental
Clinical trial activity
1 trials · 4 clinical orgs · 0 marketing orgs
Phase 1
0
Phase 2
1
Phase 3
0
Phase 4
0
Earliest trial started Jan 10, 2025 (NCT07244406)
Timeline
2020s
- Jan 1, 2025
Earliest Phase 2 Sponsor(trial)
Mechanism of action
- B-lymphocyte antigen CD19Immunity, passive
CD19 immunity, passive
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07244406 | Phase 2 | Jan 10, 2025 | Capital Medical University, Hebei Senlang Biotechnology Inc., Ltd., Peking University, Southern Medical University |
Showing 1 of 1 trials
Page 1 / 1
Organizations
Research & Development (4)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Capital Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Hebei Senlang Biotechnology Inc., Ltd. | For profit | 1 | 1 | 1 | 2025 |
| Peking University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Southern Medical University | Academic/Hospital | 1 | 0 | 1 | 2025 |
4 organizations
Page 1 / 1